Literature DB >> 18544596

A unified anti-mutant dosing strategy.

Xilin Zhao1, Karl Drlica.   

Abstract

Antimicrobial dosing is currently attracting attention as a way to minimize the emergence of resistance. Three dose-based strategies have been advocated, each with shortcomings. Focus on killing susceptible cells overlooks resistant mutant subpopulations that may be present before treatment or generated during therapy; keeping therapeutic drug concentrations above the mutant prevention concentration (MPC; resistant mutant MIC) may be overly stringent; and dosage escalation modelling uses indirect estimates of resistant mutant subpopulation susceptibility (multiples of bulk population susceptibility, MIC) rather than direct estimates from MPC. The latter is significant because MPC and MIC are discordant with multiple pathogen isolates. Combining the strategies leads to MPC-based PK/PD thresholds (e.g. AUC(24)/MPC and t > MPC) for restricting resistant subpopulation enrichment and amplification. Using MPC-based thresholds to model dosing regimens that will restrict emergence of resistance requires generation of databases in which MPC is determined for many isolates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544596      PMCID: PMC2734085          DOI: 10.1093/jac/dkn229

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  29 in total

Review 1.  The mutant selection window and antimicrobial resistance.

Authors:  Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

2.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

3.  The population dynamics of antimicrobial chemotherapy.

Authors:  M Lipsitch; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 4.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

5.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

6.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  K Metzler; G M Hansen; Peter Hedlin; Elizabeth Harding; Karl Drlica; J M Blondeau
Journal:  Int J Antimicrob Agents       Date:  2004-08       Impact factor: 5.283

8.  Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.

Authors:  J C Rodríguez; L Cebrián; M López; M Ruiz; I Jiménez; G Royo
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790

9.  High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.

Authors:  Lala M Dunbar; Richard G Wunderink; Michael P Habib; Leon G Smith; Alan M Tennenberg; Mohammed M Khashab; Barbara A Wiesinger; Jim X Xiang; Neringa Zadeikis; James B Kahn
Journal:  Clin Infect Dis       Date:  2003-08-28       Impact factor: 9.079

Review 10.  Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.

Authors:  Charles W Stratton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more
  23 in total

Review 1.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.

Authors:  Natalia R Morero; Mariela R Monti; Carlos E Argaraña
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

3.  Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus.

Authors:  Beibei Liang; Nan Bai; Yun Cai; Rui Wang; Karl Drlica; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 4.  Epidemiology, treatment and prevention of healthcare-associated urinary tract infections.

Authors:  F M E Wagenlehner; Mete Cek; Kurt G Naber; Hiroshi Kiyota; Truls E Bjerklund-Johansen
Journal:  World J Urol       Date:  2011-09-07       Impact factor: 4.226

Review 5.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

6.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

7.  In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.

Authors:  A Briales; J M Rodríguez-Martínez; C Velasco; P Díaz de Alba; J Domínguez-Herrera; J Pachón; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

8.  Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.

Authors:  Kelli Metzler; Karl Drlica; Joseph M Blondeau
Journal:  J Antimicrob Chemother       Date:  2012-11-20       Impact factor: 5.790

9.  Exploring the role of the immune response in preventing antibiotic resistance.

Authors:  Andreas Handel; Elisa Margolis; Bruce R Levin
Journal:  J Theor Biol       Date:  2008-11-08       Impact factor: 2.691

10.  Interplay in the selection of fluoroquinolone resistance and bacterial fitness.

Authors:  Linda L Marcusson; Niels Frimodt-Møller; Diarmaid Hughes
Journal:  PLoS Pathog       Date:  2009-08-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.